New method to deliver hydrogen sulfide for glaucoma treatment
Novel ocular hypotensive and neuroprotective microparticle-based hydrogen sulfide delivery system
This study is testing a new way to deliver a helpful gas called hydrogen sulfide directly into the eye to treat glaucoma, which can cause vision loss, with the hope of giving patients better options to protect their sight.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Creighton University NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10359973 on NIH RePORTER |
What this research studies
This research focuses on developing a novel delivery system for hydrogen sulfide (H2S) to treat glaucoma, a condition that leads to irreversible blindness due to retinal ganglion cell degeneration. The study aims to create a microparticle-based system that can effectively deliver H2S into the eye, addressing both the elevated intraocular pressure and providing neuroprotection to retinal neurons. By overcoming the limitations of traditional ocular delivery methods, this approach seeks to enhance the therapeutic potential of H2S in managing glaucoma. Patients may benefit from improved treatment options that could slow or prevent vision loss associated with this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma, particularly those experiencing elevated intraocular pressure.
Not a fit: Patients who do not have glaucoma or those whose condition is not related to retinal ganglion cell degeneration may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for glaucoma, potentially preserving vision for millions of patients.
How similar studies have performed: While the use of hydrogen sulfide in ocular treatments is promising, this specific delivery method is novel and has not been extensively tested in clinical settings.
Where this research is happening
Omaha, United States
- Creighton University — Omaha, United States (Active)
Researchers
- Principal investigator: Opere, Catherine a — Creighton University
- Study coordinator: Opere, Catherine a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.